| Stereochemistry | ACHIRAL |
| Molecular Formula | C17H12F9NO3S |
| Molecular Weight | 481.333 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(C1=CC=C(C=C1)N(CC(F)(F)F)S(=O)(=O)C2=CC=CC=C2)(C(F)(F)F)C(F)(F)F
InChI
InChIKey=SGIWFELWJPNFDH-UHFFFAOYSA-N
InChI=1S/C17H12F9NO3S/c18-14(19,20)10-27(31(29,30)13-4-2-1-3-5-13)12-8-6-11(7-9-12)15(28,16(21,22)23)17(24,25)26/h1-9,28H,10H2
| Molecular Formula | C17H12F9NO3S |
| Molecular Weight | 481.333 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
T0901317 is a potent, high affinity liver X receptors (LXRs) agonist. It upregulates expression of the ABCA1 gene associated with cholesterol efflux regulation and high-density lipoproteins metabolism. It also exhibits inverse agonist activity at constitutive androstane receptors (CARs). T0901317 activates bile acid farnesoid X receptors (FXRs), and it is 10-fold more potent than natural FXR ligand chenodeoxycholic acid.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 5.0 µM [EC50] | |||
| 20.0 nM [IC50] | |||
| 50.0 nM [Kd] | |||
| 2.2 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
Patents
Sample Use Guides
HEK293 cells transfected with human LXRalpha and LXR response elements were treated with increasing concentrations of T0901317 or endogenous LXR ligand, 24(S),25-epoxycholesterol (24,25-EC). Synthetic ligand induced transcriptional activity of LXRalpha nearly eightfold with EC50 value of 20 nM. T0901317 appeared significantly more active than 24,25-EC, which displayed an EC50 value of 3 uM.